CAMP4 Therapeutics Corporation (CAMP)
NASDAQ:CAMP
Want to see CAMP full AI Analyst Report?
Top Page
CAMP4 Therapeutics Corporation
(NASDAQ:CAMP)
Select Model
Select Model
Rating:47Neutral
Price Target:
$4.50
▲(0.22% Upside)
Action:Reiterated
Date:05/14/26
Overall score is held down primarily by weak financial performance (large losses and continued cash burn versus a very small revenue base). Technicals are mixed/neutral and do not provide a strong momentum tailwind, while valuation is also constrained by the negative P/E driven by unprofitability.
Positive Factors
Advancing lead program (CMP-002)
Moving CMP-002 into a planned Phase 1/2 trial is a structural de-risking step for CAMP4’s RNA-regulatory platform. Clinical proof-of-concept in a rare CNS indication with no disease-modifying options could create durable franchise value and validate the company’s modality.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow implies ongoing reliance on external financing to fund R&D. Continued cash burn can force dilutive raises or constrain program pacing, limiting strategic flexibility and increasing long-term shareholder dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Advancing lead program (CMP-002)
Moving CMP-002 into a planned Phase 1/2 trial is a structural de-risking step for CAMP4’s RNA-regulatory platform. Clinical proof-of-concept in a rare CNS indication with no disease-modifying options could create durable franchise value and validate the company’s modality.
Read all positive factors
CAMP4 Therapeutics Corporation (CAMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$233.67M
Dividend YieldN/A
Average Volume (3M)76.48K
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue Growth160.53%
EPS Growth12.32%
CountryUS
Employees55
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.27
Shares Outstanding51,925,800
10 Day Avg. Volume87,840
30 Day Avg. Volume76,478
Financial Highlights & Ratios
PEG Ratio6.16
Price to Book (P/B)3.90
Price to Sales (P/S)53.24
P/FCF Ratio-6.24
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-0.92
Enterprise Value/Gross Profit-1.21
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$8.60Price Target Upside91.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.77
Revenue Forecast (FY)$6.87M
CAMP4 Therapeutics Corporation Business Overview & Revenue Model
Company Description
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA....
How the Company Makes Money
null...
CAMP4 Therapeutics Corporation Earnings Call Summary
Earnings Call Date:Nov 21, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with strong strategic initiatives, cost reduction measures, and new product launches countered by significant revenue and gross margin declines, as well as a notable goodwill impairment.Positive Updates
Successful Migration to New Device Management System
CalAmp completed the migration of over 8.5 million devices from the legacy PULS system to the new DMCTC, enhancing functionality and benefits for TSP customers.
Negative Updates
Revenue Decline
Total revenues for Q3 FY '24 were $53.6 million, down 32% year-over-year and 13% sequentially, primarily due to reduced sales to TSP customers.
Read all updates
Q3-2024 Updates
Positive
Negative
Successful Migration to New Device Management System
CalAmp completed the migration of over 8.5 million devices from the legacy PULS system to the new DMCTC, enhancing functionality and benefits for TSP customers.
Read all positive updates
Company Guidance
During the CalAmp Corp. Q3 FY '24 Earnings Call, several key metrics and guidance were discussed. The company reported total revenues of $53.6 million, marking a 32% year-over-year and 13% sequential decline, primarily due to reduced sales to TSP customers. Adjusted EBITDA was $1 million, or 2% of revenues, which was below expectations due to lower revenue and gross margin. Recurring application subscription revenue was $17.8 million, with declines in the connected car U.K. operations offset by growth in the K-12 segment. Gross margin decreased to 33% from the previous quarter’s 36%. The call highlighted a cost-reduction initiative expected to save approximately $16 million annually, reducing the adjusted EBITDA breakeven point to $42 million in quarterly revenue. The strategic financing agreement with Lynrock Lake, involving a $45 million term loan, aims to enhance liquidity and support restructuring efforts. Looking ahead, the company anticipates a slight decrease in consolidated revenues with stable adjusted EBITDA in Q4, expecting industrial market segment revenues to normalize while seeing some recovery in TSP customer orders.CAMP4 Therapeutics Corporation Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Nov 2023 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.93M | 3.50M | 652.00K | 350.00K | 0.00 | 295.84M |
| Gross Profit | 3.00M | 1.86M | 652.00K | 350.00K | 0.00 | 121.89M |
| EBITDA | -52.24M | -50.42M | -51.39M | -50.20M | -44.12M | 7.49M |
| Net Income | -86.30M | -80.40M | -51.79M | -49.29M | -44.19M | -31.15M |
Balance Sheet | ||||||
| Total Assets | 105.46M | 117.81M | 78.31M | 54.95M | 102.55M | 402.29M |
| Cash, Cash Equivalents and Short-Term Investments | 99.21M | 109.52M | 64.04M | 38.38M | 83.19M | 91.11M |
| Total Debt | 2.12M | 1.97M | 8.65M | 11.69M | 12.39M | 209.17M |
| Total Liabilities | 74.56M | 70.10M | 15.16M | 178.68M | 180.08M | 322.11M |
| Stockholders Equity | 30.90M | 47.70M | 63.14M | -123.73M | -77.53M | 80.18M |
Cash Flow | ||||||
| Free Cash Flow | -26.25M | -29.83M | -46.00M | -44.83M | -42.57M | -17.52M |
| Operating Cash Flow | -26.25M | -29.55M | -45.56M | -44.16M | -38.54M | -4.22M |
| Investing Cash Flow | -243.00K | -243.00K | -441.00K | -678.00K | -4.03M | -7.58M |
| Financing Cash Flow | 76.10M | 75.89M | 71.66M | 301.00K | 100.16M | -2.64M |
CAMP4 Therapeutics Corporation Technical Analysis
Positive
4.49
Price Trends
4.54
Negative
4.66
Negative
4.00
Positive
Market Momentum
-0.01
Negative
50.34
Neutral
30.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAMP, the sentiment is Positive. The current price of 4.49 is above the 20-day moving average (MA) of 4.29, below the 50-day MA of 4.54, and above the 200-day MA of 4.00, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.34 is Neutral, neither overbought nor oversold. The STOCH value of 30.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CAMP.
CAMP4 Therapeutics Corporation Risk Analysis
CAMP4 Therapeutics Corporation disclosed 88 risk factors in its most recent earnings report. CAMP4 Therapeutics Corporation reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We have received orphan drug designation for CMP-001 and CMP-002 in certain jurisdictions, are pursuing orphan drug designation for CMP-002 in the United States, and may seek orphan drug designation for other product candidates in the future. We may not be able to obtain or maintain the benefits of orphan drug designation, including potential orphan drug exclusivity, and even if we do, that exclusivity may not prevent regulatory authorities from approving other competing products. Q1, 2026
CAMP4 Therapeutics Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $752.06M | -7.91 | -71.22% | ― | ― | 55.59% | |
53 Neutral | $81.50M | >-0.01 | 9999.00% | ― | ― | -63.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $59.21M | -7.81 | 26.10% | ― | ― | ― | |
49 Neutral | $53.41M | -4.61 | 76.02% | ― | ― | -13.32% | |
47 Neutral | $233.67M | -3.48 | -194.74% | ― | 160.53% | 12.32% | |
45 Neutral | $193.78M | -1.69 | -73.16% | ― | ― | -18.99% |
* Healthcare Sector Average
CAMP
CAMP4 Therapeutics Corporation
4.40
2.40
120.00%
RLMD
Relmada Therapeutics
7.21
6.60
1072.36%
BYSI
Beyondspring
1.44
-0.24
-14.29%
INKT
MiNK Therapeutics
10.94
3.84
54.08%
ARTV
Artiva Biotherapeutics, Inc.
7.99
6.01
303.54%
OSTX
OS Therapies Incorporated
1.82
0.29
18.95%
CAMP4 Therapeutics Corporation Corporate Events
Business Operations and StrategyProduct-Related Announcements
CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy
Positive
May 14, 2026
On May 14, 2026, CAMP4 Therapeutics reported new preclinical data showing that its lead antisense oligonucleotide candidate, CMP-002, significantly improved seizure threshold and reduced seizure severity in a SYNGAP1 haploinsufficient mouse model ...
Executive/Board Changes
CAMP4 Therapeutics Adds Veteran CFO MacLean to Board
Positive
Mar 24, 2026
On March 18, 2026, CAMP4 Therapeutics’ board appointed veteran biotech finance executive Michael MacLean as a Class III director, effective April 1, 2026, expanding the board from eight to nine members. MacLean, a former chief financial offi...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress
Positive
Mar 5, 2026
On March 5, 2026, CAMP4 Therapeutics reported its full-year 2025 financial results and corporate highlights, underscoring a strategic pivot toward its SYNGAP1 program and RNA-regulating platform. The company updated its investor presentation, adva...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.